BCL2 and cancer: Concordantly, to sequester unbound pro-apoptotics and thereby prevent MOMP, cancer cells generally upregulate anti-apoptotic BCL-2 family proteins and, as a result, contain higher levels of pro-apoptotic activators bound to anti-apoptotic proteins.